Biologic therapies have revolutionized the treatment of immune-mediated diseases. They are generally well tolerated; however, there are reports of malignancies associated with the use of these drugs. This case is of an adolescent with refractory Crohn's disease treated with ustekinumab, who subsequently developed Ewing's sarcoma. Patients treated with ustekinumab have reportedly developed B cell lymphoma, epithelioid sarcoma, as well as cancer of the lung, esophagus, ovary, testis, kidney, and thyroid. However, this is the first documented case of a patient treated with ustekinumab to develop Ewing sarcoma.
KondoT.Current status of proteomics in Ewing's sarcoma. Proteomics Clin Appl. 2018; 13(3):e1700130.
3.
YuH, GeY, GuoL, HuangL. Potential approaches to the treatment of Ewing's sarcoma. Oncotarget. 2017; 8(3):5523–39.
4.
BurninghamZ, HashibeM, SpectorL, SchiffmanJD. The epidemiology of sarcoma. Clin Sarcoma Res. 2012; 2(1):14.
5.
RandallRL, LessnickSL, JonesKB, et al.Is there a predisposition gene for Ewing's sarcoma?. J Oncol. 2010; 2010:397632.
6.
KouklakisG, EfremidouEI, PitiakoudisM, et al.Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer. Drug Des Devel Ther. 2013; 7:195–9.
7.
SandbornWJ, FeaganBG, FedorakRN, et al.A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008; 135(4):1130–41.
8.
MoschenAR, TilgH, RaineT. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019; 16(3):185–96.
9.
FeaganBG, SandbornWJ, GasinkC, et al.Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016; 375(20):1946–60.
10.
KotzePG, MaC, AlmutairdiA, PanaccioneR. Clinical utility of ustekinumab in Crohn's disease. J Inflamm Res. 2018; 11:35–47.
11.
VerstocktB, DeleenheerB, Van AsscheG, VermeireS. A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases. Expert Opin Drug Saf. 2017; 16(7):809–21.
12.
TengMW, BowmanEP, McElweeJJ, et al.IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015; 21(7):719–29.
13.
ZhouZ, LafleurEA, KoshkinaNV, et al.Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol Cancer Res. 2005; 3(12):685–91.
14.
FiorentinoD, HoV, LebwohlMG, et al.Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. 2017; 77(5):845.e5.
15.
PappKA, GriffithsCE, GordonK, et al.Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013; 168(4):844–54.
16.
FlorekAG, NardoneB, TharejaS, et al.Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database. Br J Dermatol. 2017; 177(5):e220–1.
17.
EvansSJ, WallerPC, DavisS. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001; 10(6):483–6.
18.
MadanchiM, ZeitzJ, BarthelC, et al.Malignancies in patients with inflammatory bowel disease: a single-centre experience. Digestion. 2016; 94(1):1–8.
19.
ChandranO, MaddenK. Ewing's sarcoma in a patient with Crohn's disease treated with adalimumab. In: Advances in inflammatory bowel disease annual conference, 2017.
